載入...
Randomized Phase II Designs
As the use of molecularly targeted agents, which are anticipated to increase overall and progression-free survival (OS and PFS), but not necessarily tumor response, has increased in oncology, there has been a corresponding increase in the recommendation and use of randomized phase II designs. Such d...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3774021/ https://ncbi.nlm.nih.gov/pubmed/19276275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2031 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|